The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice oxerexpressing human amyloid-beta 1-42

Autor: Morten Skovgaard Jensen, Andreas Søderman, Morten S. Thomsen, Henrik H. Hansen, Mark J. West, Nielsen Elsebet Ostergaard, Jens D. Mikkelsen
Předmět:
alpha7 Nicotinic Acetylcholine Receptor
Receptors
Nicotinic

Pharmacology
Nucleus Accumbens
Amyloid beta-Protein Precursor
Mice
chemistry.chemical_compound
Limbic System
Amyloid precursor protein
Attention
Neurotransmitter
Neurons
General Neuroscience
Immunohistochemistry
Nicotinic agonist
Female
Proto-Oncogene Proteins c-fos
psychological phenomena and processes
Acetylcholine
medicine.drug
Agonist
medicine.medical_specialty
medicine.drug_class
Injections
Subcutaneous

Transgene
Blotting
Western

Prefrontal Cortex
Mice
Transgenic

Nucleus accumbens
Biology
complex mixtures
Memory
Internal medicine
mental disorders
medicine
Bicyclo Compounds
Heterocyclic

Animals
Humans
Immunoprecipitation
Molecular Biology
Acetylcholine receptor
Amyloid beta-Peptides
Dose-Response Relationship
Drug

Bridged Bicyclo Compounds
Heterocyclic

Peptide Fragments
Mice
Inbred C57BL

Endocrinology
nervous system
chemistry
biology.protein
sense organs
Neurology (clinical)
Developmental Biology
Zdroj: Aarhus University
Søderman, A, Thomsen, M S, Hansen, H H, Nielsen, E Ø, Jensen, M S, West, M J & Mikkelsen, J D 2008, ' The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice oxerexpressing human amyloid-beta 1-42 ', Brain Research, vol. 1227, pp. 240-47 .
Søderman, A, Thomsen, M S, Hansen, H H, Nielsen, E Ø, Jensen, M S, West, M J & Mikkelsen, J D 2008, ' The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42 ', Gene Expression Patterns, vol. 1227, pp. 240-7 . https://doi.org/10.1016/j.brainres.2008.06.062
Popis: Recent studies have demonstrated that amyloid-beta1-42 (Abeta1-42) binds to the nicotinergic alpha7 acetylcholine receptor (alpha7 nAChR) and that the application of Abeta1-42 to cells inhibits the function of the alpha7 nAChR. The in vivo consequences of the pharmacological activation of the alpha7 nAChR have not been examined. The aim of this study has been to evaluate the efficacy of alpha7 nAChR modulators in transgene mice that overexpress human amyloid precursor protein and accumulate Abeta1-40 and Abeta1-42. In accordance with observations in human Alzheimer tissues, we show here through the use of co-immunoprecipitation that human Abeta-immunoreactive peptides bind to mice alpha7 nAChR in vivo. Agonists of the alpha7 nAChR improve memory and attentional properties and increase immediate early gene expression in the prefrontal cortex and the nucleus accumbens. We show that acute systemic administration of the alpha7 nAChR agonist SSR180711 (10 mg/kg) result in a significant increase in Fos protein levels in the shell of nucleus accumbens in wild-type mice, but has no effect in the transgene mice. There were fewer cell bodies expressing Fos in the prefrontal cortex of transgene mice, and in this region no induction was achieved after administration with SSR180711 in either of the two groups. These results suggest that overexpression of human Abeta peptides perhaps via direct interaction with alpha7 nAChR, inhibit alpha7 nAChR-dependent neurotransmission in vivo and emphasize that clinical trials testing alpha7 nAChR agonists should be related to the content of Abeta peptides in the patient's nervous system.
Databáze: OpenAIRE